CN Bio is a leading organ-on-a-chip (OOC) company that offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines.

Our range of lab-benchtop PhysioMimix™ microphysiological systems (MPS) enables researchers to model human biology in the lab through rapid and predictive 3D human tissue-based studies that harness microfluidic technology to provide nutrients and mimic blood flow. The technology bridges the gap between traditional cell culture and human studies, advancing towards the simulation of human biological conditions to support the accelerated and more efficient development of new therapeutics, whilst reducing the dependence on animal model usage.

CN Bio’s MPS support researchers that require reliable, data-rich, in vitro studies, to uncover the mechanisms of disease (e.g non-alcoholic steatohepatitis (NASH), Hepatitis B virus, or COVID-19 infection), identify novel therapeutic targets, or investigate drug efficacy, pharmacokinetics and potential toxicity.

Next-generation PhysioMimix OOC models span a range of organ types, including lung, liver and gut. Single organs can be linked together into multi-organ systems to simulate processes such as drug absorption and metabolism, or to understand interactions between organs, such as inflammation.

Harnessing these assays, our portfolio of MPS, NASH-in-a-box kit, 3D validated cells, compatible consumable plates and contract research services have been developed to address drug development bottlenecks across a range of therapeutic areas, including metabolic and infectious diseases, oncology, and inflammation.